


3.1.1 Grants received from Government and non-governmental agencies for research projects / endowments in the institution during the last five years (INR in Lakhs)

Name of the research project/ endowment	Name of the Principal Investigator/Co-	Department of Principal	Year of Award	Amount Sanctioned	Duration of the project	Name of the Funding	Type (Government/non-Government)
Synthesis and development of Novel, Stable QD's with suitable device for Pharmaceutical, healthcare and Biotech industry applications	Dr Anuvrat Sharma	Pharmaceutics	Applied Proposal	49.88 Lakhs (Budget of Proposal submitted)	1.5 years	BIRAC	Government
Workshop on harmonization of Curriculum-Industry academic meet	Dr Arifa Begum SK	Pharmaceutics	Applied for Workshop	75000 (Budget of Proposal submitted)	Applied in 2023	PCI	Government
Development and evaluation of polyherbal formulation with potent anti-epileptic activity	Dr.Sumalatha govindu & Dsouza Marina	Pharmacology	2022	84666	3 years	AICTE	Government
Targetted drug delivery in the treatment of diseases of heart and vasculature using sterically stablized long circulating stealth liposomes and combination with depot polymeric scaffolds	Dr.Srinivas Nimmagadda & Sampurna Chengalvala	Pharmacetics	2022	616666	3 Years	AICTE	Government

Workshop on recent trends in Clinical Data Management	Dr. B Sridevi& Dr. Arifa Begum SK	Pharmacy Practic	2022	15000	1 Year	Telengana Academy of sciences	Non-Government
Development and evaluation of polyherbal formulation with potent anti-epileptic activity	Dr.sumalatha govindu & Dsouza Marina	Pharmacology	Proposal Submitted	84666 (Budget of Proposal submitted)	Applied in 2021	AICTE	Government
Targetted drug delivery in the treatment of diseases of heart and vasculature using sterically stabkized long circulating stealth liposomes and combination with depot polymeric scaffolds	Dr.Srinivas Nimmagadda &Sampurna Chengalvala	Pharmacetics	Proposal Submitted	616666 (Budget of Proposal submitted)	Applied in 2021	AICTE	Government
One day National seminar on Zebra fish: A super fast and precise animal model for A to Z Human diseases	Dr A V Badarinath & Dr S Gurunath	Pharmacology	Proposal Submitted	90000	Applied in 2020	ICMR	Government

Development and Standardization of Broad Spectrum herbomineral Nutrient tablets for Universal Cancer prevention	Dr A V Badarinath & Dr N Harishankar	Pharmaceutics	Proposal Submitted	97800 (Budget of Proposal submitted)	Applied in 2019	Ministry of AYUSH	Government
Preclinical Anti-Diabetic studies of Polyherbal Formulation on Streptozotocin induced diabetes	Dr Mrinmay Das	Pharmaceutics	Proposal Submitted	50000 (Budget of Proposal submitted)	Applied in 2019		
Intranasal insitu gel Nanoparticles of Anticancer drugs for Brain	Dr Y Phalguna	Pharmaceutics	Proposal Submitted	50000 (Budget of Proposal submitted)	Applied in 2019		
Development of Instrument tobacco smoke induced lung cancer chamber as effective natural	Dr A V Badarinath	Pharmaceutics	Proposal Submitted	50000 (Budget of Proposal submitted)	Applied in 2019		


PRINCIPAL
 Bharat Institute of Technology
 Mangalpally (V), Ibrahimpetnam (M),
 R.R. Dist - 501 510, Telangana.

3.1.1 Grants received from Government and non-governmental agencies for research projects/endowments in the institution during the last five years (INR in Lakhs)

DVV Comment: Please provide a list of research project grants received in Assessment years. Include details about the award type, the agencies that granted at and the amount.

Grants applied and released:

S.no	Name of the research project/Endowment	Name of the investigator/Co-investigator	Department of Principal Investigator	Applied year	Released year	Amount Sanctioned	Name of the Funding Agency
1	Development and evaluation of polyherbal formulation with potent anti-epileptic activity	Dr Sumalatha Govindu & Dsouza Marina	Pharmacology	2021	2022	84666	AICTE
2	Targeted drug delivery in the treatment of diseases of heart and vasculature using sterically stabilized long circulating stealth liposomes and combination with depot polymeric scaffolds	Dr Srinivas Nimmagadda and Sampurna Chengalvala	Pharmaceutics	2021	2022	616666	AICTE
3	Workshop on recent trends in clinical data management	Dr B Sridevi & Dr. Arifa Begum SK.	Pharmacy practice	2022	2022	15000	Telengana Academy of sciences

ALL INDIA COUNCIL FOR TECHNICAL EDUCATION
Nelson Mandela Marg, Vasant Kunj,
New Delhi 110070

RPS - Sanction Letter

File No. 8-133/FDC/RPS/POLICY-1/2021-22

Date: _____

The Drawing and Disbursing Officer
All India Council for Technical Education
Nelson Mandela Marg,
Vasant Kunj, New Delhi 110070,

Sub: Release of a sum of Rs. 74082/- being the 1st installment of the total grant of Rs. 84666/- for conduct of Project under Research Promotion Scheme (RPS) during the financial year 2021-22.

Sir,

With reference to the proposal submitted by the institute, this is to convey the sanction of the Council for payment of Rs. 74082/- (Rupees Seventy Four Thousand Eighty Two Only) as 1st installment out of a total approved grant in-aid of Rs. 84666/- for conduct of a Project under the Research Promotion Scheme (RPS), as per details given below:

I.	Name and address of the Beneficiary Institution (University / College / Institution)	: Registrar / Director / Principal, BHARAT INSTITUTE OF TECHNOLOGY, MANGALPALLY VILLAGE, IBRAHIMPATNAM MANDAL -501510, TELANGANA
II.	Principal Investigator's Name & Dept./Course	: Dr. SUMALATHA GOVINDU (PHARMACY)
III.	Co-Principal Investigator's Name & Dept.	: DSOUZA MARINA (PHARMACOLOGY)
IV.	Grant in aid Sanctioned	: Rs. 84666/- (Rs. 63499/- for non recurring and Rs. 21167/- for recurring expenditure)
V.	Amount to be Released during the year 2021-22 (as 1 st installment)	: Rs. 74082/- (Rs. 63499/- Full amount of non-recurring & Rs. 10583/- recurring i.e. 50 % of total sanctioned recurring grant)
VI.	Project Duration	: 3 Years
VII.	Title of the Project	: Development and Evaluation of Polyherbal formulation with potent antiepileptic activity

I. Release of funds:

- The amount of the grant shall be drawn by the Drawing and Disbursing Officer (DDO), All India Council for Technical Education, New Delhi on the Grants in aid bill and shall be debursed to and credited to the account of BHARAT INSTITUTE OF TECHNOLOGY, MANGALPALLY VILLAGE, IBRAHIMPATNAM MANDAL - 501510, TELANGANA through PFMS.
- The sanctioned grant-in aid is debitable to the Major Head "601.12.a (RPS Plan)" Gen. and is valid for payment during the financial year 2021-22.
- The sanction issues in exercise of the powers delegated to the Council. It is also certified that grant-in-aid is being released in conformity with the rules and principles of the Scheme.
- The grant in-aid is being released in conformity with the Terms & Conditions as well as norms of the scheme as already communicated and also being communicated in this letter.

II. Maintenance of account by the Institute/PI:

- Funds covered by this grant shall be kept separately and would not be mixed up with other funds so as to know the amount of interest accrued on the grant.
- The grant is intended to cover items of expenditure/equipment approved by AICTE.
- Acknowledgement of receipt of grant and letter of acceptance of terms and conditions is to be submitted to AICTE within 15 days from the receipt of the grant to the following address:

Director (Faculty Development Cell), AICTE, Nelson Mandela Marg, Vasant Kunj, New Delhi-110070

Contd. 2/-

R.K. Net - Sumalatha
Mangalpally (V), Ibrahimpatnam (M)
R.R. Dist - 501 510, Telangana

4. The accounts of the grantee will be opened for test check by the Council or Comptroller & Auditor General of India or by any officer designated by them.
5. The Principal and PI of the institute are requested to verify the correctness of the undermentioned bank account/RTGS/PFMS details submitted by them along with the Proposal, in which the grant is being released. In case of any omission, the same should be reported to AICTE immediately along with refund of entire grant:-

Institute Pan No.	Bank Name	Bank Branch	Bank Branch Add.	Account Holder Name	Account Type	Account Number	IFSC Code
AAATC25 5/1	STATE BANK OF INDIA	BONGLOOR	H. NO 2-84 GANGANAGAR COLONY, BONGLOOR VILLAGE, IBRAHIMPATNAM MANDAL, R.R. DISTRICT, TELANGANA- 501510	R. L. I. PRINCIPAL GENERAL ACCOUNT	Saving Account	62101095523	SBIN0021069

6. The grantee Institution shall observe all financial norms and guidelines as prescribed by the AICTE/Government of India from time to time. Grantee institution must follow GFR guidelines in procuring the sanctioned items and maintain an audited record of assets acquired wholly or substantially out of the grant-in aid and a register for assets shall be maintained by the Institute in the prescribed form i.e. GIR-19.
7. Interest accrued on the sanctioned grant-in-aid will be reported and refunded to AICTE and not adjusted against the subsequent installment.

III. General Instructions:

- It should be ensured that no RPS project in favour of the same P.I. has been sanctioned during the last 03 years before utilizing this amount and the matter be brought to the notice of this Council immediately in case a faculty is sanctioned multiple RPS Projects.
- The duration of Project is 03 years and the date of release of the grant by AICTE shall be taken as the date of commencement of the project. The Registrar/Director/Principal shall intimate about the receipt of the grant to AICTE. Any Expenditure, incurred prior to issuance of this Sanction Order, would not allowed to be adjusted in the grant and if the University/Institution do not take-up the project work within 6 months of the receipt of the grant, approval shall *ipso facto* lapse and the Institute has to necessarily refund the entire grant to AICTE along with interest within a month. In case the grant is not refunded within said duration 18% interest will be levied on it. The grant has to be refunded to AICTE, through RTGS as per details given below:

Account Number	55113199952
Name of the Account Holder	Member Secretary, AICTE, New Delhi
Bank Name	State Bank of India
Branch Name	Shashtri Bhawan, New Delhi
IFSC Code	SBIN0050203

3. The Institute may constitute a Project Monitoring Committee (PMC). The composition of the PMC shall be as under:
- Principal/Director of the institution (Chairperson)
 - Two HODs from institute (Members)
 - In case of private institute one subject expert from government institute, not below the rank of Associate Professor (Member)
 - Coordinator of the project (Member Secretary)
4. The grant shall be utilized strictly for the purpose as specified in the sanction letter. Re-appropriation of funds from one Head to another is strictly not permitted viz. Recurring and non-recurring Heads. Further, the equipment(s)/item(s) purchased should be as per the specifications and individual item-wise costs sanctioned by AICTE, and not taking the total grant sanctioned as one entity. Item-wise purchase cost shall be matched with the sanctioned cost, and the cost of item purchased below the sanction cost shall be restricted as actual cost. If the item purchase cost is higher than its sanctioned cost, the cost shall be restricted to the sanctioned cost and the additional amount shall be met by the Institute from its own resources.
5. Similarly, the recurring grant can be used for the items (non-recurring) sanctioned by the AICTE. No money be used for going abroad to attend Conference / seminars. However, for presenting a Paper in a Seminar / Conference within the country, the travel expenses may be met from the recurring grant.

Contd. 13/

R. K. Net

Mangalpur, Telangana
R.R. Dist - 501 510, Telangana.

6. No request for additional grant over and above the sanctioned grant shall be considered by the AICTE. The additional amount, if any, expended beyond the sanctioned grant shall be met by the institute from its own resources.
7. The institute/University shall not charge any overheads on this Project and will provide all the administrative support and timely release of grant to PI for completion of the Project.
8. The grantee shall utilize grants only on approved items as per list of equipment attached. However, if the grantee wishes to recast the Project, approval of Council must be obtained for the revised item of expenditure and they will maintain proper accounts of the expenditure as per the norms/procedures of AICTE/Government of India. The revised proposal should be within the total grant sanctioned and duly supported with reasons and recommendations of the Project Monitoring Committee (PMC).
9. The assets acquired wholly or substantially out of All India Council for Technical Education's grant shall not be disposed or encumbered or utilized for the purpose other than those for which the Grant was given without a proper sanction of the All India Council for Technical Education.
10. Each project sanctioned by AICTE is assigned a specific Reference Number, which is given on pre page. All correspondence address to AICTE regarding the project must quote this number alongwith year of sanction of the project, otherwise correspondence may not be entertained.
11. The grantee shall follow the terms and conditions of Research Promotion Scheme (RPS) as laid down by the Council from time to time.

IV. Submission of documents by the institute/PI to AICTE:

A. Documents to be submitted within one month of completion of each financial year:

- i. Annual Progress Report, indicating therein the number of patents, publications or any other achievement.
- ii. Utilization Certificate, Audited Utilization Certificate, Receipt & Payments, Statement of Expenditure.
- iii. Audited record of assets acquired wholly or substantially out of the grant-in-aid and a register for assets in the prescribed form i.e. GFR-19.
- iv. Separate Bills/vouchers related to Non recurring and recurring expenditures duly signed & stamped by the PI & Head of the institution.
- v. Stock entry register duly verified by the Store in charge and PI & counter signed by Head of institution.

B. Documents to be submitted within two month of completion of the Project:

- i. The consolidated Utilization Certificate (UC) and Receipt & Payment Account for the Project duration, duly audited.
- ii. Consolidated audited statement of expenditure, to the effect that the grant has been utilized for the purpose for which it has been sanctioned. It should contain the head-wise break up of expenditure made from the grant-in-aid provided by the Council.
- iii. Project Completion Report duly signed & stamped by the PI & Head of the institution and Project Evaluation Committee (PEC) Members.
- iv. Principal Investigator/institute to submit the Feed Back Form in AICTE format.
- v. The prescribed formats for submission of necessary mandatory documents and Terms & Conditions may please be downloaded from www.aicte-india.org/schemes/research-innovations-development-schemes.

Note: Any deviation from the above said time schedule will cause serious action against the institute.

Contd.....4/-

Laxar Institute of Technology
Mangalpally (V), Ibrahimpatnam (M),
R.R. Dist - 501 510, Telangana.



v. Approved List of Items under Non-recurring grant:

S. No.	Approved Items (As per proposal)	No. of Units	Amount recommended (in Rs.)
A.	Non-recurring		
i)	Actophotometer	1	
ii)	Electroconvulsimeter	1	Rs. 63499/-
iii)	HPTLC	1	
B.	Recurring i.e. 50% of total approved recurring grant) for Contingencies & Consumables only		Rs. 10583/-
	Grand Total (A) + (B)		Rs. 74082/-

Copy forwarded for information and necessary action to:

1. REGISTRAR / DIRECTOR / PRINCIPAL,


BHARAT INSTITUTE OF TECHNOLOGY,
MANGALPALLY VILLAGE,
IBRAHIMPATNAM MANDAL -501510,
TELANGANA

2. NAME OF PRINCIPAL INVESTIGATOR,

Dr. SUMALATHA GOVINDU,
(PHARMACY)
BHARAT INSTITUTE OF TECHNOLOGY,
MANGALPALLY VILLAGE,
IBRAHIMPATNAM MANDAL -501510,
TELANGANA

3. OFFICE OF DIRECTOR GENERAL OF AUDIT
GENERAL REVENUES, AGCR BUILDING
I.P. ESTATE, NEW DELHI-110002.

4. GUARD FILE



(Col. B. Venkat)
Director (FDC)

PROCESSED
Bharat Institute of Technology
Mangalpally (V), Ibrahimpatnam (M),
R.R. Dist - 501 510. Telephone:

ALL INDIA COUNCIL FOR TECHNICAL EDUCATION

Nelson Mandela Marg, Vasant Kunj,
New Delhi 110070

RPS - Sanction Letter

File No. 8-132/FDC/RPS/POLICY-1/2021-22

Date: _____

The Drawing and Disbursing Officer
All India Council for Technical Education
Nelson Mandela Marg,
Vasant Kunj, New Delhi 110070,

Sub: Release of a sum of Rs. 539582/- being the 1st installment of the total grant of Rs. 616666/- for conduct of Project under Research Promotion Scheme (RPS) during the financial year 2021-22

Sir,
With reference to the proposal submitted by the institute, this is to convey the sanction of the Council for payment of Rs. 539582/- (Rupees Five Lakh Thirty Nine Thousand Five Hundred Eighty Two Only) as 1st installment out of a total approved grant in aid of Rs. 616666/- for conduct of a Project under the Research Promotion Scheme (RPS), as per details given below:

I.	Name and address of the Beneficiary Institution (University / College / Institution)	: Registrar / Director / Principal, BHARAT INSTITUTE OF TECHNOLOGY, MANGALPALLY VILLAGE, IBRAHIMPATNAM MANDAL -501 510, TELANGANA
II.	Principal Investigator's Name & Dept./Course	: Dr. SRINIVAS NIMMAGADDA (PHARMACY)
III.	Co-Principal Investigator's Name & Dept.	: SAMPURNA CHENGALVALA (PHARMACEUTICS)
IV.	Grant in aid Sanctioned	: Rs. 616666/- (Rs. 462499/- for non-recurring and Rs. 154167/- for recurring expenditure)
V.	Amount to be Released during the year 2021-22 (as 1 st installment)	: Rs. 539582/- (Rs. 462499/- Full amount of non recurring & Rs. 77083/- recurring i.e. 50 % of total sanctioned recurring grant)
VI.	Project Duration	: 3 Years
VII.	Title of the Project	: Targeted Drug Delivery in the Treatment of Diseases of Heart and Vasculature Using Sterically Stabilized, Long Circulating, Stealth Liposomes and their Combination with Depot Polymeric Scaffolds

I. Release of funds:

- The amount of the grant shall be drawn by the Drawing and Disbursing Officer (DDO), All India Council for Technical Education, New Delhi on the Grants in-aid bill and shall be disbursed to and credited to the account of BHARAT INSTITUTE OF TECHNOLOGY, MANGALPALLY VILLAGE, IBRAHIMPATNAM MANDAL - 501510, TELANGANA through PTMS
- The sanctioned grant-in aid is debitable to the Major Head "601.12.a (RPS Plan)" Gen. and is valid for payment during the financial year 2021-22.
- The sanction issues in exercise of the powers delegated to the Council. It is also certified that grant in aid is being released in conformity with the rules and principles of the Scheme.
- The grant in-aid is being released in conformity with the Terms & Conditions as well as norms of the scheme as already communicated and also being communicated in this letter.

II. Maintenance of account by the Institute/PI:

- Funds covered by this grant shall be kept separately and would not be mixed up with other funds so as to know the amount of interest accrued on the grant.
- The grant is intended to cover items of expenditure/equipment approved by AICTE.
- Acknowledgement of receipt of grant and letter of acceptance of terms and conditions is to be submitted to AICTE within 15 days from the receipt of the grant to the following address:

Director (Faculty Development Cell), AICTE, Nelson Mandela Marg, Vasant Kunj, New Delhi 110070

PRINCIPAL
Bharat Institute of Technology
Mangalpally (M), Ibrahimpatnam (M),
R.R. Dist - 501 510, Telangana.

Contd. 2/

R.K.Nel.

4. The accounts of the grantee will be opened for test check by the Council or Comptroller & Auditor General of India or by any officer designated by them
5. The Principal and PI of the institute are requested to verify the correctness of the undermentioned bank account/RTGS/PFMS details submitted by them alongwith the Proposal, in which the grant is being released. In case of any omission, the same should be reported to AICTE immediately along with refund of entire grant.

Institute Pan No.	Bank Name	Bank Branch	Bank Branch Add	Account Holder Name	Account Type	Account Number	IFSC Code
AAATC25571	STATE BANK OF INDIA	BONGLOOR	H. NO. 284, GANGANAGAR COLONY, BONGLOOR VILLAGE, IBRAHIMPATNAM MANDAL, R.P. DISTRICT, TELANGANA 501510	R.T. PRINCIPAL GENERAL ACCOUNT	Saving Account	62101095523	SBIN0021069

6. The grantee Institution shall observe all financial norms and guidelines as prescribed by the AICTE/Government of India from time to time. Grantee institution must follow GIR guidelines in procuring the sanctioned items and maintain an audited record of assets acquired wholly or substantially out of the grant-in-aid and a register for assets shall be maintained by the Institute in the prescribed form i.e. GIR 19.
7. Interest accrued on the sanctioned grant-in-aid will be reported and refunded to AICTE and not adjusted against the subsequent installment.

III. General Instructions.

1. It should be ensured that no RPS project in favour of the same P.I. has been sanctioned during the last 03 years before utilizing this amount and the matter be brought to the notice of this Council immediately in case a faculty is sanctioned multiple RPS Projects.
2. The duration of Project is 03 years and the date of release of the grant by AICTE shall be taken as the date of commencement of the project. The Registrar/Director/Principal shall intimate about the receipt of the grant to AICTE. Any Expenditure, incurred prior to issuance of this Sanction Order, would not be allowed to be adjusted in the grant and if the University/Institution do not take-up the project work within 6 months of the receipt of the grant, approval shall *ipso facto* lapse and the Institute has to necessarily refund the entire grant to AICTE along with interest within a month. In case the grant is not refunded within said duration 18% interest will be levied on it. The grant has to be refunded to AICTE, through RTGS as per details given below:

Account Number	55113199952
Name of the Account Holder	Member Secretary, AICTE, New Delhi
Bank Name	State Bank of India
Branch Name	Shashtri Bhawan, New Delhi
IFSC Code	SBIN0050203

3. The Institute may constitute a Project Monitoring Committee (PMC). The composition of the PMC shall be as under:

- Principal/Director of the institution (Chairperson)
- Two HODs from institute (Members)
- In case of private institute one subject expert from government institute, not below the rank of Associate Professor (Member)
- Coordinator of the project (Member Secretary)

4. The grant shall be utilized strictly for the purpose as specified in the sanction letter. Re-appropriation of funds from one Head to another is strictly not permitted viz. Recurring and non-recurring Heads. Further, the equipment(s)/item(s) purchased should be as per the specifications and individual item wise costs sanctioned by AICTE, and not taking the total grant sanctioned as one entity. Item wise purchase cost shall be matched with the sanctioned cost, and the cost of item purchased below the sanction cost shall be restricted as actual cost. If the item purchase cost is higher than its sanctioned cost, the cost shall be restricted to the sanctioned cost and the additional amount shall be met by the institute from its own resources.
5. Similarly, the recurring grant can be used for the items (non-recurring) sanctioned by the AICTE. No money be used for going abroad to attend Conference / seminars. However, for presenting a Paper in a Seminar / Conference within the country, the travel expenses may be met from the recurring grant.

Contd...3/-

PRINCIPAL
Bharat Institute of Technology
Mangalpally (V), Ibrahimpatnam (R),
R.R. Dist - 501 510. Telangana.

6. No request for additional grant over and above the sanctioned grant shall be considered by the AICTE. The additional amount, if any, expended beyond the sanctioned grant shall be met by the Institute from its own resources.
7. The institute/University shall not charge any overheads on this Project and will provide all the administrative support and **timely release of grant to PI** for completion of the Project.
8. The grantee shall utilize grants only on approved items as per list of equipment attached. However, if the grantee wishes to recast the Project, approval of Council must be obtained for the revised item of expenditure and they will maintain proper accounts of the expenditure as per the norms/procedures of AICTE/Government of India. **The revised proposal should be within the total grant sanctioned and duly supported with reasons and recommendations of the Project Monitoring Committee (PMC).**
9. The assets acquired wholly or substantially out of All India Council for Technical Education's grant shall not be disposed or encumbered or utilized for the purpose other than those for which the grant was given except as per sanction of All India Council for Technical Education.
10. Each project sanctioned by AICTE is assigned a specific Reference Number, which is given on pro-forma. All correspondence address to AICTE regarding the project must quote this number alongwith year of sanction of the project, otherwise correspondence may not be entertained.
11. The grantee shall follow the terms and conditions of Research Promotion Scheme (RPS) as laid down by the Council from time to time.

IV. Submission of documents by the institute/PI to AICTE:

A. Documents to be submitted within one month of completion of each financial year:

- i. Annual Progress Report, indicating therein the number of patents, publications or any other achievement.
- ii. Utilization Certificate, Audited Utilization Certificate, Receipt & Payments, Statement of Expenditure.
- iii. Audited record of assets acquired wholly or substantially out of the grant in aid and a register for assets in the prescribed form i.e. GFR 19.
- iv. Separate Bill/vouchers related to Non-recurring and recurring expenditures duly signed & stamped by the PI & Head of the institution.
- v. Stock entry register duly verified by the Store-in charge and PI & counter signed by Head of institution.

B. Documents to be submitted within two month of completion of the Project:

- i. The consolidated Utilization Certificate (UC) and Receipt & Payment Account for the Project duration, duly audited.
- ii. Consolidated audited statement of expenditure, to the effect that the grant has been utilized for the purpose for which it has been sanctioned. It should contain the head wise break up of expenditure made from the grant-in aid provided by the Council.
- iii. Project Completion Report duly signed & stamped by the PI & Head of the institution and Project Evaluation Committee (PEC) Members.
- iv. Principal Investigator/institute to submit the Feed Back Form in AICTE format.
- v. The prescribed formats for submission of necessary mandatory documents and Terms & Conditions may please be downloaded from www.aicte-india.org/schemes/research-innovations-development-schemes.

Note: Any deviation from the above said time schedule will cause serious action against the institute.

Contd. 4/

PRINCIPAL
Eharat Institute of Technology
 Mengalpally (V), Ibrahimpatnam Dist.
 R.R. Dist - 501 510, Telangana.

V. Approved List of Items under Non-recurring grant.

S. No.	Approved Items (As per proposal)	No. of Units	Amount recommended (in Rs.)
A.	Non-recurring		
i)	Lyophilizer	1	
ii)	Probe Sonicator	1	Rs. 462499/-
iii)	Solid Phase Extraction (SPE) Instrument	1	
B.	Recurring i.e. 50% of total approved recurring grant) for Contingencies & Consumables only		Rs. 77083/-
	Grand Total (A) + (B)		Rs. 539582/-

Copy forwarded for information and necessary action to.

1. REGISTRAR / DIRECTOR / PRINCIPAL,

BHARAT INSTITUTE OF TECHNOLOGY,
MANGALPALLY VILLAGE, IBRAHIMPATNAM
MANDAL -501510, TELANGANA

2. NAME OF PRINCIPAL INVESTIGATOR,

Dr. SRINIVAS NIMMAGADDA,
(PHARMACY)
BHARAT INSTITUTE OF TECHNOLOGY,
MANGALPALLY VILLAGE, IBRAHIMPATNAM MANDAL -501510,
TELANGANA

3. OFFICE OF DIRECTOR GENERAL OF AUDIT
GENERAL REVENUES, AGCR BUILDING
I.P. ESTATE, NEW DELHI-110002.

4. GUARD FILE


(Col. B. Venkat)
Director (FDC)

Principal Investigator
Bharat Institute of Technology
Mangalpally (V), Ibrahimpatnam (M)
A.R. Dist - 501 510, Telangana.

“One Day Workshop on Recent Trends in Clinical Data Management”
Organized by



Bharat Institute of Technology
Mangalpally, Ranga Reddy, Telangana
Approved by PCI, AICTE and Affiliated to JNTU-H
In Association with



TAS

Telangana Academy of Sciences
Tarnaka, Hyderabad, Telangana- 500017

March 26th 2022

SCHEDULE

Welcome address	9.30 AM - 9.40 AM	Principal
Inaugural address by Chief Patron & Patron	9.40 AM- 9.50 AM	Shri. Ch. Venugopal reddy, Chairman, Bharat institute of Technology &
Introduction of speaker	9.50 AM – 10.00AM	
Morning Session	10.00AM To 12.15 PM	
Handed over to guest speaker	12.15 AM To 12.30P M	
Concluding remarks for morning session (discussion)		
Lunch (12.30-1.30 PM)		
Afternoon session for practical workshop program	1.30 PM To 2.40P M	
Evaluation Test	2.40 To 3.10 PM	
Prize Distribution	3.30 To 3.45 PM	
Vote of thanks	3.45 To 4 PM	

CONVENOR: DR BHIMA SRIDEVI
 Department of Pharmaceutical Chemistry
 Bharat Institute of Technology
 Email. ID:sridevibhima@bitpharmacy.org

CO-CONVENOR: DR ARIFA BEGUM SK
 Department of Pharmaceutical Chemistry
 Bharat Institute of Technology
 Email. ID: arifabegum@bitpharmacy.org



BHARAT INSTITUTE OF TECHNOLOGY

Approved by AICTE & PCI, New Delhi and Affiliated to JNTU, Hyderabad)
Sponsored by: CHINTA REDDY MADHUSUDHAN REDDY EDUCATIONAL SOCIETY
Mangalpally (Village), Ibrahimpatnam (Mandal), Ranga Reddy District - 501 510.
Ph : 08414-252265, Fax : 08414-252645, E-mail : btlpharm@yahoo.com

Ref.:

9th April 2022
Hyderabad

To
The Regional Coordinator,
Rangareddy Dist. Regional Centre,
Telangana Academy of Sciences,
Hyderabad.

Subject: Regarding Approval of financial assistance for expenses incurred for organizing the workshop.

1 Dr.Bhima Sridevi, working as Asst. Professor at Bharat Institute of Technology Ibrahimpatnam. It is our immense pleasure that our college has been granted sponsorship for the conduction of Workshop from TELANGANA ACADEMY OF SCIENCES. As per the discussions, Bharat Institute of Technology in Association with Telangana Academy of Sciences, Hyderabad has organized One day Workshop on Recent Trends in Clinical Data Management dated on March 25th 2022. Expenses incurred on workshop were done towards:

1. Guest Speakers honorarium-10,000 /-
2. Banner, Certificates expenditure at Radha Hitech print solutions- 1740/-
3. Mementos for speakers and winners-500/-
4. Photos and documentation-500/-
5. Stationery purchases-1930/-
6. Publicity - 500/-

Please note all the expenditure along with supporting documents was submitted. I request you sir please transfer the amount of Rs.15,000/- to the college bank account. Account no: 62101095523

IFS code: SBIN0021069.

Thanking you Sir

Yours Sincerely

Dr.Bhima Sridevi



R. J. K. S. /
PRINCIPAL
Bharat Institute of Technology




BHARAT INSTITUTE OF TECHNOLOGY
Approved by AICTE & PUL, New Delhi and Affiliated to JNTU, Hyderabad)
Sponsored by : CHINTA REDDY MADHUSUDHAN REDDY EDUCATIONAL SOCIETY
Mangalpally (Village), Ibrahimpatnam (Mandal), Rangareddy District - 501 510.
Ph : 08444-252255, Fax : 08444-252445, E-mail : bhpharma@yahoo.com


Utilization certificate

This is to certify that Bharat Institute of Technology in Association with Telangana Academy of Sciences, Hyderabad organized "One day Workshop on Recent Trends in Clinical Data Management" as per the assurance of financial assistance from TAS confirming with an email of cosponsor ship dated 16th February 2022. Assured amount has been utilized for the conducting of the event on March 25th 2022, expenditure incurred in organizing the program with original bills has been attached for your kind reference and perusal.


Signature of Convener

Date:-


Signature of the Head of the Institution
Date:-



PRINCIPAL
Bharat Institute of Technology
Mangalpally (V), Ibrahimpatnam (M)
R.R. Dist. Pin: 501510

Grants applied & not yet released:

S.no	Name of the research project/Endowment	Name of the investigator/Co-investigator	Department of Principal Investigator	Applied year	Name of the funding agency	Status
1	Synthesis and development of Novel, Stable QD's with suitable device for Pharmaceuticals, Healthcare and Biotech Industry applications	Dr Anuvrat Sharma	Pharmaceutics	Applied	BIRAC	Applied & not yet released
2	Workshop on harmonization of Curriculum industry academic meet	Dr Arifa Begum SK	Pharmaceutics	2023	PCI	Applied & not yet released
3	One day national seminar on Zebra-fish: A super-fast and precise animal model for A-to-Z human diseases	Dr A V Badarinath and Dr S Gurunath	Pharmacology	2020	ICMR	Applied & not yet released
4	Development and standardization of Broad spectrum herbo-mineral nutrient tablets for universal cancer prevention	Dr A V Badarinath and Dr N Harishankar	Pharmaceutics	2019	Ministry of AYUSH	Applied & not yet released
5	Pre-clinical anti-diabetic studies of polyherbal formulation on streptozotocin induced diabetic rats	Dr Mrinmay Das	Pharmaceutics	2019	-	Applied & not yet released
6	Intranasal in-situ gel nanoparticles of anticancer drugs for Brain cancer	Dr Y Phalguna	Pharmaceutics	2019	-	Applied & not yet released
7	Development of instrument tobacco smoke induced lung cancer chamber as effective natural animal model	Dr A V Badarinath	Pharmaceutics	2019	-	Applied & not yet released

117-433-2400

PARTICULARS OF THE APPLICANT

Applicant Name : Innatura Scientific Pvt Ltd			
Contact Details		Address2:	
Address1:	HNo_7-152, Mye Villas, Opp FCI Godown road, Mallapu		
Street/Village:	Hyderabad	City/Town:	Hyderabad
State:	TELANGANA	Country:	India
Pincode/Zip:	500076	Landline:	91-863-9107187
Mobile:		Website:	https://www.inaturas.com/
Fax:			
Brief Background Of The Incubatee			
Date of incorporation of company			
2018			
Number of Years since Registration			
5			
Registration Certificate Of Company			
View file			
PAN Card			
View file			
Memorandum of Association of company			
No File Uploaded			
Article of Association of company			
No File Uploaded			
Audited Financial Statements (Annual Report and Balance Sheet)			
View file			
Are the Shares Of the Company held to the Extent Of 51% By Indian Citizens (including NRIs) ?			
Yes			
Shareholding Pattern of the Company Indicating Name And Address Of Foreign Shareholders, Overseas Corporate Bodies And Shares Held By NRIs			
View file			
Number of shareholders			
2			
Passports of Shareholders			
View file			
Is this Company a subsidiary to a Parent Company?			
No			
Is any promoter holding 20% or more shares of the applicant company, a co-promoter of another company(ies)/ a part another LLP?			
No			
Is any partner of the LLP, a co-partner of another LLP(s)/ a co-promoter of another company(ies)?			
No			
Do you have a Functional Laboratory of your own ?			
Yes			

Shareholding Pattern Of The Company

Shareholding Pattern Of The Company

S.No	Category of shareholder	Number of shareholders	Total number of shares	Total share holding as % of total number of shares
Shareholding of promoter & Promoter Group				
)	Indian			
a)	Foreign:- NRI	2	2	100
)	Foreign:- Foreign individual	0	0	0
	Total	2	2	0
Public Shareholding				
)	Indian			
a)	Foreign:- NRI	0	0	0
)	Foreign:- Foreign individual	0	0	0
	Total	0	0	0
	Grand Total	2	2	100

Project Coordinators Details		Organization	Innatura Scientific Pvt Ltd
Title	Dr	Last Name	Duddukuri
First Name	Nandan	Gender	Male
Designation	Chief Scientific Officer	Landline	+91-040-8639107187
Email	innaturasolutions@gmail.com	Resume	View file
Mobile	+91-9966161722		
Passport Copy	No File Uploaded		

Team Members		Organization	Innatura Scientific Pvt Ltd
Title	Dr	Last Name	Gatadi
First Name	Srikanth	Gender	Male
Designation	Scientific Officer	Landline	+91-040-8639107187
Email	gatadi.srikanth8@gmail.com	Resume	View file
Mobile	+91-7013738653		
Associated with any other BIG project (ongoing/completed)		No	

Team Members		Organization	Bharat Institute of Technology Pharmacy
Title	Dr	Last Name	Sharma
First Name	Anuvrat	Gender	Male
Designation	Director	Landline	+91-040-8639107187
Email	director@bitpharmacy.org	Resume	View file
Mobile	+91-7993640745		
Associated with any other BIG project (ongoing/completed)		No	

Scientific Advisors		Organization	Innatura Scientific Pvt Ltd
Title	Dr	Last Name	GUBBALA
First Name	VENKATA RAMESH	Gender	Male
Designation	Scientific Advisor	Area(s) of Expertise	Nanotechnology
Affiliation	CBIT	Landline	+91-040-8639107187
Email	gubbala.v.ramesh@gmail.com	Resume	View file
Mobile	91-8076909068		

PROPOSAL SUMMARY

Proposal Summary [Provide a brief one paragraph overview of the proposal, i.e. the idea and the problem it may solve and project plan.]

The proposed project focuses on the synthesis and development of novel and stable Quantum Dots (QDs) for various applications in pharmaceutical, healthcare, and biotech businesses. QDs are a type of nanomaterial that have unique optical and electronic properties, making them useful in a range of applications such as medical imaging, drug product tracking, product development, drug delivery and biosensors, etc. The aim of this proposed project is to design, synthesize and develop new QDs with improved stability and biocompatibility, making them suitable for use in above mentioned industries. This project also aims to develop a suitable device that can effectively be utilized using these novel QDs in real-world applications. The ultimate goal of the project is to contribute to the advancement of these industries by providing new, innovative solutions based on QD technology. This project is expected to have a significant impact on the development of new technologies and products for the pharmaceutical, healthcare, and biotech industries.

Please upload a concept note explaining the technology with necessary figures and diagrams :

File Uploaded

Briefly state the Objectives and Proposed Approach

Describe how the proposed project addresses the problem. Clarify the current status of the innovation.]
The description should cover the following points:

- Strategy and/or methodology of work.
- Scope and boundaries of the work, including any issues that will not be covered.
- Data analysis (sample size, data collection)

The objectives of the proposed project are as follows:

- To Design, synthesize and develop novel and stable quantum dots (QDs) with improved stability and bio compatibility.
- To develop suitable device that can effectively utilize these novel QDs in real-world applications.
- To contribute to the advancement of the Pharmaceutical, Healthcare, and Biotech industries by providing new, innovative solutions based on QD technology.

The proposed approach to achieve these objectives is as follows:

- Strategy and methodology of work: The project will be approached using a multi-disciplinary view, combining expertise in material science, chemistry, and biomedical engineering. A combination of synthetic and characterization techniques will be used to synthesize the QDs, and the biocompatibility and stability of the QDs will be evaluated. The development of suitable device will involve the integration of these novel QDs into existing technologies or the development of new technologies.
- 2. Scope and boundaries: The scope of the project will focus on the synthesis and development of novel and stable QDs for use in the Pharmaceutical, Healthcare, and Biotech industries. The project will not cover the commercialization of the developed products.
- 3. Data analysis: The sample size for the study will be determined based on statistical considerations and the results will be analyzed using appropriate statistical tools. Data collection will involve the use of various characterization techniques, including optical spectroscopy, electron microscopy, XRD and in vitro & in vivo studies to evaluate the biocompatibility and stability of the QDs. The data collected will be used to validate the suitability of the developed QDs and devices in real-world applications.

3. Novelty

[Explain how your idea is innovative and how it is different from the existing products in the markets or current state-of-the-art. Tabular representation of the difference between your idea and the other products in market or competitive product which are under development will be appreciated. Concrete market data is encouraged.]

The proposed project aims to address a key challenge in the development of quantum dots for use in the Pharmaceutical, Healthcare, and Biotech industries, which is the stability and biocompatibility of the QDs. The proposed project is innovative because it aims to synthesize and develop novel and stable quantum dots with improved biocompatibility and stability, which is a significant improvement over the current state-of-the-art.

2. Currently, several QDs available in the market suffer from a lack of stability and biocompatibility, which limits their use in the pharmaceutical, healthcare, and biotech industries. The novel QDs developed in this project will have improved stability and biocompatibility, making them more suitable for use in these industries. Further, the development of suitable devices to utilize these novel quantum dots will be a significant innovation in the field, as it will enable the effective utilization of these quantum dots in real-world applications.

3. Table: Comparison of proposed project and existing products in the market

Feature	Proposed Project	Existing Products
Stability	Improved	Limited
Biocompatibility	Improved	Limited
Device Integration	Suitable devices developed	Limited integration with existing devices

16. The proposed project is innovative and offers several advantages over existing products in the market. The improved stability and biocompatibility of the novel quantum dots, along with the development of suitable devices, will make them more attractive for use in the pharmaceutical, healthcare, and biotech industries. The concrete market data will be evaluated and analyzed once the project is completed and the results are available..No File Uploaded

Opportunity

What is the potential societal and market impact? Provide details of the problem you propose to solve.]

The proposed project has the potential to have a significant impact on the Pharmaceutical, Healthcare and Biotech industries. By synthesizing and developing Novel and Stable QDs with improved biocompatibility and stability, the project aims to address a key challenge in the development of QDs for use in these industries. The improved stability and biocompatibility of the novel quantum dots, along with the development of suitable devices to utilize them, will enable the effective utilization of quantum dots in real-world applications in these industries.

In the pharmaceutical industry, QDs have the potential to revolutionize medical imaging and drug delivery. The improved stability and biocompatibility of the novel QDs will make them more suitable for use in these applications, providing more effective and safer treatments for patients.

In the healthcare industry, quantum dots have the potential to be used in biosensors and diagnostic tools, providing faster and more accurate diagnoses. The improved stability and biocompatibility of the novel quantum dots, along with the development of suitable devices, will make these tools more effective and accessible.

In the biotech industry, QDs have the potential to be used in a range of applications, including gene expression analysis and protein labeling. The improved stability and biocompatibility of the Novel QDs, along with the development of suitable devices, will make these applications more effective and efficient.

In summary, the proposed project has the potential to have a significant impact on the pharmaceutical, healthcare, and biotech industries by providing new, innovative solutions based on quantum dot technology. The improved stability and biocompatibility of the novel quantum dots, along with the development of suitable devices, will enable the effective utilization of quantum dots in real-world applications in these industries.

Challenges or risk factors associated with the project

What are the challenges and risk factors that you envision which may affect this project?]

What are the critical success factors/potential barriers?

There are several challenges and risk factors associated with the proposed project:

Synthesis and development of stable and biocompatible quantum dots: The development of stable and biocompatible quantum dots is a complex and challenging task. There is a risk that the proposed synthesis and development methods may not result in the stability and biocompatibility of the quantum dots, which would limit their use in the pharmaceutical, healthcare, and biotech industries.

Integration with devices: The development of suitable devices to utilize the novel quantum dots is also a complex task. There is a risk that the proposed devices may not function as intended or may not be suitable for use in real-world applications.

Biocompatibility testing: The biocompatibility of the novel quantum dots must be thoroughly tested to ensure that they are safe for use in the pharmaceutical, healthcare, and biotech industries. The testing process is time-consuming and there is a risk that the results may not be favorable, which would limit the use of the novel quantum dots.

Regulatory approval: In order for the novel quantum dots and associated devices to be used in the pharmaceutical, healthcare, and biotech industries, they must undergo a required regulatory approval process. There is a risk that the Novel QDs and associated devices may need some additional data, which will limit their further development.

Competition: The development of quantum dots and associated devices is a rapidly evolving field, and there is a risk that other companies or research institutions may develop similar or superior products, reducing the market potential for the proposed project.

The critical success factors for the proposed project include:

Successful synthesis and development of stable and biocompatible quantum dots: The success of the proposed project depends on the ability to synthesize and develop stable and biocompatible quantum dots that meet the desired specifications.

Successful integration with devices: The success of the proposed project also depends on the ability to develop suitable devices that can effectively utilize the unique properties of quantum dots, such as their fluorescence and other specific applications in the pharmaceutical, healthcare, and biotech industries.

Favorable biocompatibility testing results: The biocompatibility of the Novel QDs must be thoroughly tested, and favorable results are critical for the success of the proposed project.

Regulatory approval: The regulatory approval process is a critical success factor for the proposed project, as the Novel QDs and associated devices data are limited.

6. Has any preliminary work been carried out? Give status of work done

If no, please provide the background details.

QDs are a type of nanoscale material that have unique optical and electronic properties, making them useful for a range of applications, including imaging and sensing. In recent years, there has been growing interest in developing quantum dots that are stable and biocompatible for use in the pharmaceutical, healthcare, and biotech industries.

The development of biocompatible and stable quantum dots requires a thorough understanding of the synthesis and characterization of these materials. This includes optimizing the size, shape, and composition of the quantum dots, as well as ensuring that they are non-toxic and do not interfere with biological systems.

In addition, the integration of quantum dots with suitable devices is also a critical component of the development process. This includes developing devices that can effectively utilize the unique properties of quantum dots, such as their fluorescence and other specific applications in the pharmaceutical, healthcare, and biotech industries.

Overall, the field of quantum dots and their potential applications in the pharmaceutical, healthcare, and biotech industries is an active area of research and development, and there have been numerous advances in recent years.

7. Please provide current and expected Technology Readiness Level (TRL)

Current TRL

TRL - 1

This project is yet to take off as per the plan mentioned above.

Expected TRL

TRL - 4

The critical milestones would be updated as per the below mentioned details.

8. Proposed end-outcomes (Your BIG Project is expected to result in the following end-outcomes).

A Product for customers

An intellectual property right for licensing or sale

Future Plan of Commercialization

What do you envision to be the key next step to making impact with this innovation (e.g., sponsored research support, licensing, venture financing)? What is the time frame?

Commercialization plan should indicate:

Market entry strategy.

Timelines and Milestones.

Data analysis (sample size, data collection)

A comprehensive business/commercialization plan for the stable QD technology solutions would include the following steps: Scale up.

Market research and analysis: Conduct market research to determine the size and growth potential of the relevant industry

segments pharmaceutical and biotechnology, bioimaging, and supply chain management and to identify potential customers and competitors.

Product development and validation: Further develop and validate the technology solutions through collaboration with industry partners, universities, or research institutions.

Intellectual Property protection: Obtain patents and other forms of intellectual property protection to secure the technology solutions and provide a competitive advantage in the market.

Go-to-market strategy: Develop a go-to-market strategy to commercialize the technology solutions, including pricing, distribution and marketing strategies. This could involve licensing the technology to industry players or launching a standalone product.

Business and financial planning: Develop a comprehensive business plan and financial model to ensure the viability of the commercialization efforts and to secure funding from investors or strategic partners.

Industrial collaboration: Establish partnerships and collaborations with relevant industry players to jointly develop and commercialize the technology solutions.

Exit strategy: Develop an exit strategy for incubation, which could involve selling the company or spinning off the technology solutions into a standalone entity. The exit strategy for industrial collaboration would depend on the needs of the partnership

agreement.

Overall, the commercialization plan for the stable QD technology solutions would involve a systematic and comprehensive approach to bring the technology to market, including market research, product development, IP protection, go-to-market strategy, business and financial planning and exit strategy.

10. Intellectual Property

i. Does the applicant or the applicant company own any IP related to this project. If yes, give details. (Please mention Patent Number, Patent Title and Patent Assignee)

The proposed project will enter in to IP related activities as and when it will achieve critical milestones. As a part of strategy, the IP Cell with required expertise will be a part of this project.

ii. List Of Patents That Appear To Cover Any Part Of The Technology Of Interest Or Similar (And Possibly Overlapping) Technologies And Thereby Restrict The Freedom-To-Operate In The Envisaged Area. (Please mention Patent Number, Patent Title and Patent Assignee)

NA

iii. If there are patents that are overlapping and may restrict FTO, does the applicant have the required license/s to practise these inventions for the purposes of the proposed project? Please provide license agreement details if any or provide information of the proposed next steps to obtain said license/s.

NA

11. Relevant References.

1. Zhigao et al. Highly stable quantum dot light-emitting diodes with improved interface contacting via violet irradiation. Adv. Mater. 34 2022 2106276. Sci. 615 2023 156339
2. Bright and Stable Quantum Dot Light-Emitting Diodes. Adv. Mater. 34 2022 2106276.
3. A.M. Smith, S. Dave, S. Nie, L. True, X. Gao, Multicolor quantum dots for molecular diagnostics of cancer, Expert Rev. Diagn. 6 2006 231-244.
4. J.Q. Duan, Y. Ma, M. Che, B. Zhang, Y. Zhang, Y. Li, W. Zhang, S. Sang, Fluorescent carbon dots as carriers for intracellular doxorubicin delivery and track, J. Drug Deliv. Sci. Technol. 49 2019 527-533.
5. V.G. Reshma, P.V. Mohanan, Quantum dots: applications and safety consequences, J. Lumin. 205 2019 287-293.
6. G.N. Vajubhai, S.K. Kailasa. Glutathione-ascorbic acid-functionalized molybdenum oxide quantum dots-based fluorescent sensor for the detection of isoniazid drug in pharmaceutical samples, 287 2023 122041.
7. J.D. Schiffman, R.G. Balakrishna, Quantum dots as fluorescent probes: synthesis, surface chemistry, energy transfer mechanisms, and applications, Sens. Actuators B Chem. 258 2018 1191-1214.
8. F. Mollarasouli, V. Serafian, S. Campuzano, P. Anez-Sede, J.M. Pingarr, K. Asadpour-Zeynali, Ultrasensitive determination of receptor tyrosine kinase with a label-free electrochemical immunosensor using graphene quantum dots-modified screen-printed electrodes, Anal. Chim. Acta 1011 2018 28-34.
9. M. Roushani, A. Valipour, M. Bahrami, The potentiality of the functionalized nitrogen and thiol-doped graphene quantum dots (GQDs-NS) to stabilize the antibodies in the designing of human chorionic gonadotropin immunosensor, Nanochem. Res. 4 2019 20-26.
10. Y. Qian, J. Feng, H. Wang, D. Fan, N. Jiang, Q. Wei, H. Ju, Sandwich-type signaloff photoelectrochemical immunosensor based on dual suppression effect of PbS quantum dots/Co3O4 polyhedron as signal amplification for procalcitonin detection with improved stability and biocompatibility. Sens. Actuators B Chem. 300 2019 127001.

12. Please upload declaration document on ethical/legal/safety/regulatory issues involved, if any .

No File Uploaded

13. Presentation

[View file](#)

14. Undertaking by the Principal Investigator with regards to the originality of proposal submitted

[View file](#)

Any other information relevant to the project

Please Upload the Relevant Document

[View file](#)

[View file](#)

[View file](#)

OBJECTIVE AND TIMELINES

PROPOSAL OBJECTIVES & WORK PLAN

Objective1: Design, synthesis and development of a Novel and Stable Quantum Dots QDs with improved stability and biocompatibility.

Methodology/Experimental Design Detailed Work Plan :

The synthesis plan and development strategy will be shared as an when it is ready

Alternate Strategies:

Multiple synthesis strategies will be worked out parallelly

Objective2: Development of suitable validated stability indicating analytical methods

Methodology/Experimental Design Detailed Work Plan :

A Validated analytical method will be developed for various analytical techniques

Alternate Strategies:

Alternate analytical methods and tools will be studied

Sl. No	
1	Sign
2	Des
3	Qu
	co
	D
	th

Methodology/Experimental Design Detailed Work Plan :

Objective 4: To contribute to the advancement of the Pharmaceutical, Healthcare, and Biotech Industries by providing new, innovative solutions based on QD technology

Intermediate Strategies:

1. Suitable device architecture will be studied

2. Various applications of the Novel QDs in Pharmaceutical, Healthcare and Biotech Industries will be explored

3. Different possible real life applications will be explored

Activities	Month Of Start Of Activity	Month Of End Of Activity	Indicators Of Progress
OBJECTIVE :Design, synthesis and development of a Novel and Stable Quantum Dots QDs with improved stability and bio compatibility.			
Design, synthesis and development of a Novel and Stable Quantum Dots QDs with improved stability and bio compatibility.	0	4	The synthesis plan and development strategy will be shared as an when it is ready
OBJECTIVE :Development of suitable validated stability indicating analytical methods			
Development of suitable validated stability indicating analytical methods	5	7	A Validated analytical method will be developed for various analytical techniques
OBJECTIVE :Development of suitable device that can effectively utilize these novel QDs in real-world applications.			
Development of suitable device that can effectively utilize these novel QDs in real-world applications.	8	10	A suitable device to process the fluorescence pattern of the novel QDs will be developed and validated
OBJECTIVE :To contribute to the advancement of the Pharmaceutical, Healthcare, and Biotech industries by providing new, innovative solutions based on QD technology			
To contribute to the advancement of the Pharmaceutical, Healthcare, and Biotech industries by providing new, innovative solutions based on QD technology	11	16	Various applications of the Novel QDs in Pharmaceutical, Healthcare and Biotech industries will be explored

QUANTIFIABLE MILESTONES

Sl. No	Milestone Name	Month Of End Of Activity(In Months)
1	Signing of Contract	--
2	Design, synthesis and development of a Novel and Stable Quantum Dots QDs with improved stability and bio compatibility.	4
3	Development of suitable device that can effectively utilize these novel QDs in real-world applications.	10

BUDGET DETAILS

Non Recurring Cost(Rs. In Lakhs)		Total
S.No	Equipments/Accessories	10.00
1	10.00	
Recurring Cost(Rs. In Lakhs)		Total
Human Resources(A)	Consumables(B)	Other Heads(C)
14.88	20.00	5.00
		39.88

OTHER FINANCIAL DETAILS

Have you approached any other organisation/agency for financial support for the present activity? Please give details.

Not approached

4	To contribute to the advancement of the Pharmaceutical, Healthcare, and Biotech Industries by providing new, innovative solutions based on QD technology	16
5	Submission Of Report	

Details Of Equipment Proposed To Be Acquired Through BIRAC's Grant

S.No	Infrastructure/Equipment	Capacity	Quantity	Specific Requirement In The Project	Estimated Value(Rs.in Lakhs)
1	Stability chambers	2	2	stability test	5.00
2	Animal house & related expenditure	1	1	safety tests	3.00
3	autoclave	1	2	synthesis	2.00
Total :10.00					

HUMAN RESOURCES TO BE INVOLVED

Human Resource to be involved with the project

S.No	Position	No Of Positions	Qualification	Exp.(Years)	Age(In Years)	Hired Duration (in months)	Role In Project	Monthly Salary(In Lakhs)	Total Cost(In Lakhs)
1	Research Scientist	1	PhD	5.00	32	16.0	Synthesis and stability studies	0.50	8.00
2	Research Associate	1	MSc	2.00		16.0	Design and Synthesis	0.25	4.00
3	Research Associate	1	BTech	2.00	27	16.0	stability, safety studies	0.18	2.88
Total : 14.88									

CONSUMABLES DETAILS

Through BIRAC's Contribution

S.No	Items	Quantity	Units(e.g:- g/ml etc.)	Approximate Cost (Rs.in lakhs)	Justification For The Requirement
1	HPLC Comuns	4	4	5.00	Purification
2	Detectors	3	3	3.00	analysis
3	reference standards	5	5	3.00	analysis
4	solvents chemicals	3	10	6.00	synthesis
5	Deep freezer	1	1	1.00	storage
6	Autoclave	2	2	2.00	synthesis
Total Amount Required For Consumables: 20.00					

JUSTIFICATION FOR OTHER RECURRING HEADS

Through BIRACs Contribution

S.No	Other Cost (Rs.in lakhs)	Justification
1	5.00	for special studies and collaboration with professionals in the same work and Travelling for conferences and workshops for dissemination of information

PHARMACY COUNCIL OF INDIA

**APPLICATION FOR THE CONDUCT OF WORKSHOP UNDER THE
SCHEME TO ORGANISE SEMINAR SYMPOSIUM AND WORKSHOP IN PHARMACY
COLLEGE**

TOPIC: "Harmonization of Curriculum - Industry Academia Meet"

**From BHARAT INSTITUTE OF TECHNOLOGY, MANFALPALLY,
HYDERABAD, TELANGANA**

Region /state :Telangana

1. ACTIVITY : WORKSHOP

2. GEOGRAPHICAL COVERAGE: State or inter-state level

3. Name of workshop : Hormonization of Curriculum Industry Academia meet

4. Dates : from: 16/6/23 TO 17/6/23

Total number of dates : 2 Days

5. Venue: BHARAT INSTITUTE OF TECHNOLOGY (PCI-239)

6. NAME AND ADDRESS OF ORGANISING COLLEGE:

- COLLEGE NAME: Bharat Institute of Technology
- DEPARTMENTS :Pharmacology, pharmaceuticals, pharmacy
practice, pharmaceutical chemistry, pharmaceutical analysis
- ADDRESS: Mangalpally, Ibrahimpatnam ranga reddy dst.
- PIN: 501510
- PH.NO:9640909041,9640909044
- EMAIL: principal.bit@biet.ac.in
- NAME OF THE AFLILIATING UNIVERSITY : JNTUH

- ACCREDITATION OF COLLEGE : NAAC/NBA : NAAC – B
Grade

7. NAME DESIGNATION OF CONVENOR / CO-ORDINATOR/ CO-COORDINATOR

- **CONVENOR:** Dr. ANUVRAT SHARMA
Director & Professor
- **CO-ORDINATOR:** Dr. ARIFA BEGUM SK
Principal & professor
- **CO-COORDINATOR:** Dr. NAMRATHA SUNKARA, Professor

The workshop intends to provide a forum for brainstorming by extending opportunities to the academicians and industry personals with national education policy (NEP)-2020

OBJECTIVE

The basic objective is to bring together academicians and expert from different pharma industry to facilitate the exchange of knowledge and innovation.

SCHEDULE OF THE WORKSHOP

DAY-1	ACTIVITIES	DURATIONS	NAME OF EXPERT
SESSION 1	Introduction : discussion on the objective of the workshop	30 min	N. KAMALAKAR RAO GENERAL MANAGER FR&D, HITECH PHARM PVT LT, BOLARAM, SANGAREDDY PH: 9502592310
SESSION 2	Defining the core competencies of pharmacy profession and program outcomes	1 hr	BRIJENDRA KUMAR SHUKLA, PLANT HEAD AND TECHNICAL DIRECTOR, HINDUSTAN LABORATORIES LTD, PALGHAR ,MAHARASTRA PUNE PH: 02242460505
SESSION 3	Discussion and deliberation competencies of pharmacy profession and program outcomes	1.5hr	
LUNCH BREAK		1 hr	
SESSION4	Introduction to curriculum development and identification of critical factors of curriculum development	1hr	PCI NOMINATED EXPERT & MR. SHARATH TEKADE RN PHARMA CONSULTY/PARTNER QA MANUFACTURING PH: 8884225025
SESSION 5	Segregation of subject expert (industrial pharmacy, pharmaceutical chemistry, quality assurance , pharmacology and pharmacognosy & photochemistry) and brain storming session for framing the syllabus		
DAY-2			
Session -1	Brain storming session : Recap review on the outcomes from the Suggestions /proposal made for framing the syllabus fixing the duration of topics fxing credit points and to redefine the process of evaluation & assessment of student	1 hr	Dr. GARAPATY RAMA PRASAD RA CHEM PHARMA LTD MADHAPUR , HYD TELANGANA -81 PH: 040-44758595 & R PURNIMA PORTFOLIO MANAGER WELDING PHARMA 9885553332
Session	Discussion on the syllabus of the subject from participants belongs to that subject group	1.5hr	
Lunch break			
Session -3	Arrangement of the curriculum and final draft syllabus.	1.5 hr	Ms Kavitha B GVK BIOSCIENCES,

concluding remarks

9949256510

The grant may be used for the following items:

S.NO		AMOUNT
1	ORGANIZING SECRETARY	5000/-
2	CODRDINATOR	5000/-
3	CO-COORDINATOR	2500/-
4	HONORARIUM PER PERSON	5000/- (PER PERSON)
5	PATICIPANTS PER PERSON	1000/-(50 PERSON)
6	TA	3000/-
7	PRE CONFERENCE PRINTING	5000/-
8	FOOD	48500/-


PRINCIPAL

BHARAT INSTITUTE OF TECHNOLOGY

MANHGALPALLY, RANGA REDDY, TELANGANA

PCI-239

9640909041

principal.bit@biet.ac.in





INDIAN COUNCIL OF MEDICAL RESEARCH
V. Ramalingawami Bhawan, Ansari Nagar, Post Box No. 4911
New Delhi - 110029

Application for grant of financial assistance for organizing Seminar

1. **Title of Seminar.**
One Day National Seminar on "ZEBRA FISH; A SUPER FAST AND PRICISE ANIMAL MOLEL FOR 'A to Z' HUMAN DISEASES"
2. **Name of Institution seeking financial assistance.**
Bharat Institute of Technology (Pharmacy),
Accredited by NAAC,
Approved by AICTE & PCI,
Affiliated to JNTU Hyderabad,
Mangalpalli – 501 510(Village), Ibrahimpatnam (Mandal),
Hyderabad, Ranga Reddy District, Telangana.
3. **Name, designation and address of Organising Secretary & Convener with Pin Code including telephone/Mobile/Fax/e-mail address.**

Organising Secretary:

Dr. A.V.Badarinath, M.Pharm., Ph.D.,
In-charge, Research and Development Cell,
Bharat Institute of Technology (Pharmacy),
Mangalpalli – 501 510(Village), Ibrahimpatnam (Mandal),
Hyderabad, Ranga Reddy District, Telangana.
9440916296, avbadrinatha@gmail.com

Convener:

Dr. S.Gurnath, M.Pharm, Ph.D.,
Deputy In-charge, Research and Development Cell,
Bharat Institute of Technology (Pharmacy),
Mangalpalli – 501 510(Village), Ibrahimpatnam (Mandal),
Hyderabad, Ranga Reddy District, Telangana.
9966555091, s.gurunath1979@gmail.com

4. **Date (s) and place of organizing Seminar.**
One Day Seminar: **Date** 09-05-2020, Day – Saturday.
Place: Bharat Institute of Technology (Pharmacy),
Mangalpalli – 501 510(Village), Ibrahimpatnam (Mandal),
Hyderabad, Ranga Reddy District, Telangana.
5. **Grant requested for from ICMR : Rs.90,000/-**

6. (a) Detailed Programme i.e. name of speakers and their topics/titles of papers/lectures etc. (date & time wise) along with list of participants may be submitted. Indicate confirmed speakers. (National & International)
Kindly include names of speakers only after getting their consent or else mention clearly- consent awaited/ not yet confirmed.

Enclosures

1.Detailed Program

2.List of Participants

- (b) In what way is the Seminar expected to contribute to the existing knowledge in the field?

Existing Scenario: Existing knowledge of animal models (Rats, Mice) in “drug discovery” for various human diseases has lot of limitations. The four major limitations are consumption of long time, applicable only to certain human diseases imprecise results, high cost consumption. This scares the scientists and pharmaceutical investors to enter into the field of drug discovery which results in lack of innovation of new drugs from past few decades. With the existing models, the drug discovery, output and patent process becomes tedious. Hence numbers of patents are not coming out. This makes India poor in Innovation Ranking and Global Competitiveness Rankings.

Seminar Outcome: This seminar will introduce “Super Animal Model” (Zebra Fish) to all research people in and around Hyderabad. This seminar will be “single shot answer” for all the above issues and definitely this seminar will remain as “breakthrough” in the drug discovery research. Sure this seminar gives zeal to all scholars, scientists, students, company scientists. The impact of this seminar comes live in short and makes our India to get good Innovation rank.

- (c) Has any Association/Chapter received any grant from ICMR during the last two years for organizing Seminar/Symposium? If so, give details year-wise and quote the ICMR letter No. and date, in tabular form under the following heads:-

Name of the Association	Year	Amount	Letter No.& date	Purpose	Name of the Seminar/ Symposium	Whether UC/Report submitted
-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-

- (d) What is the total expenditure anticipated? Please give details under various heads.

S. No	Particulars	Income	Expenditure
1	Registration Fee (300 Participants)	0	--
2	Honorarium (4 Speakers X 10,000)	--	40,000
3	Lunch for Participants (300 Participants) (Members 300 x Each meal 200/-)	--	60,000
4	Kits for Participants (300 Participants) (Members 300 x Each kit 200/-) (File, Pen, Pad, Seminar CD, Material, ID card)	--	60,000
5	Tea, Snacks (300 x 66/-) (Morning – Tea only) (Evening – Tea with Samosa/Biscuits)	--	20,000
6	Sponsor from Bharat Institute of Technology	90,000	--
7	Sponsor from ICMR	90,000	--
	Balance Match	1,80,000	1,80,000

7. Details of grant requested/received from other agencies like DST, DBT, CSIR, UGC, INSA, NAMS and ICAR for the proposed Seminar/Symposium/Conference/Workshop:

Name of the Agency	Grant Requested	Grant Received	Grant received or expected	Items for which grant has been asked for
-Nil-	-Nil-	-Nil-	-Nil-	-Nil-

8. (a) Name of the authority who will be responsible for submitting the audited statement of accounts/Utilization Certificate.

Organising Secretary:

Dr. A.V.Badarinath, M.Pharm., Ph.D.,
In-charge, Research and Development Cell,
Bharat Institute of Technology (Pharmacy),
Mangalpalli – 501 510(Village), Ibrahimpatnam (Mandal),
Hyderabad, Ranga Reddy District, Telangana.
9440916296, 7995649019, avbadrinatha@gmail.com

- (b) The Organizing Secretary would have to submit a brief summary of scientific activity & copy of proceedings report within a period of three months.

Yes. Report will be sent with in a period of three months.

- (c) Please indicate whether you are willing to accept up to two nominees of the Council for participation in the Seminar without any registration charges:

Yes. Surely we will accept up to two nominees without registration charges.

(d) Name of the authority in whose favour payment of grant is to be released.

Bank Name: State Bank of India
Branch Name: Bongloor Outer Ring Road, Hyderabad
Account Name: BIT Principal General Account
Account Number: 62101095523
IFSC Code: SBIN0021069

9. Check list:

(i) 4 copies of application –

Yes. Included

(ii) 4 copies of detailed programme i.e. name of Speakers and their topics/titles of papers/lectures etc. (date, time-wise).

Yes. Included

(iii) 4 copies of list of participants.

Yes. Included

(iv) Kindly send the soft copy in Words:-icmrseminars@gmail.com

Yes. Mailed

10. It may please be noted that incomplete application/after receiving the due date will not be considered and no correspondence will be entertained.


Signature
Organizing Secretary

Signature
Executive Authority


Signature
Head of the Institution

Date:

Place:

Human Resource Planning and Development Indian Council of Medical Research

Financial assistance for organizing
Seminars/Symposia/Conferences/ Workshops

ELECTRONIC CLEARING SERVICE (CREDIT CLEARING) / REAL TIME GROSS
SETTLEMENT (RTGS) FACULTY FOR RECEIVING PAYMENTS

A. DETAILS OF ACCOUNT HOLDER :-

1	NAME OF ACCOUNT HOLDER/INSTITUTE	BIT PRINCIPAL GENERAL ACCOUNT
2	REGISTERED MOBILE NUMBER	9440916296
3	COMPLETE CONTACT ADDRESS	Bharat Institute of Technology (Pharmacy), Mangalpalli – 501 510(Village), Ibrahimpattam (Mandal), Hyderabad, Ranga Reddy District, Telangana.
5	TELEPHONE NUMBER / FAX / E MAIL	7995649019, avbadrinatha@gmail.com
6	TITLE OF THE SEMINAR	"ZEBRA FISH; A SUPER FAST AND PRICISE ANIMAL MOLEL FOR 'A to Z' HUMAN DISEASES"

B. BANK ACCOUNT DETAIL :- (Fellow Bank Account Details)

1	BANK NAME	STATE BANK OF INDIA
2	BRANCH NAME WITH COMPLETE ADDRESS, TELEPHONE NUMBER AND EMAIL	H.No- 2-84, Ganga Nagar Colony, Bongloor Village, Pin Code – 501 510, Ibrahimpattam (Mandal), Hyderabad, Ranga Reddy District, Telangana. 08414-252479, agmsecreg2@sbhyd.co.in
3	WHETHER THE BRANCH IS COMPUTERIZED ?	YES
4	WHETHER THE BRANCH IS RTGS ENABLED? IF YES, THEN WHAT IS THE BRANCH'S IFSC CODE	SBIN0021069
5	IS THE BRANCH ALSO NEFT ENABLED?	Yes
6	TYPE OF BANK ACCOUNT (SB / CURRENT)	Current
7	COMPLETE BANK ACCOUNT NUMBER (LATEST)(fellow account)	00000052210042139
8	MICR CODE OF BANK	500002420

I hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all for reasons of incomplete or incorrect information. I would not hold the user institution responsible.

Date : 
(Signature & Seal of Organizer)

(Signature of Head of Department)

Certified that the particulars furnished above are correct as per our records.

(..... Signature & Seal of A.O. of the Concerned Division in ICMR.....)



ANNEXURE-1

MINISTRY OF AYURVEDA, YOGA & NATUROPATHY, UNANI, SIDDHA AND
HOMOEOPATHY

APPLICATION FOR GRANT-IN-AID OF EXTRA MURAL RESEARCH PROJECTS IN AYUSH

Section-A

1. Title of the Research Project:

DEVELOPMENT AND STANDARDISATION OF BROADSPECTRUM HERBOMINERAL
NEUTRIENT TABLETS FOR UNIVERSAL CANCER PREVENTION.

2. Details of the Institution submitting the research project:

Name: Bharat Institute of Technology, (Pharmacy),

Postal address: Bharat Institute of Technology, Mangalpally - 501510, Ibrahimpatnam,

Ranga Reddy District, Telangana.

Telephone: 9963477875 E-mail: bitpharm.hr@gmail.com

3. In case of Individuals submitting the Research project:

Not applicable, Application is in the name of institution

4. Name and Designation of

Principal investigator:

Dr. A.V.Badarinath, M.Pharm., Ph.D.,

Professor of Pharmaceutics,

In-Charge: Research and Development Cell,

Bharat Institute of Technology (Pharmacy),

Mangalpally - 501510, Ibrahimpatnam, Ranga Reddy District, Telangana.

Phone: 7995649019, 9440916296, E-Mail: avbadrinatha@gmail.com

Co-Investigator(s):

Dr. N.Harishankar, Ph.D.,

Scientist 'E'/Dy.Director'

National Centre for Laboratory Animal Sciences.

National Institute of Nutrition. Taranaka.

HYDERABAD - 500 007. (A.P)

Telephone: 00-91-40-27197202

FAX: 00-91-40-27003317, E-mail: hsnemani2000@yahoo.com

5. Duration of Research Project: 3 years

- | | |
|--|----------|
| i) Period required for pre-trial preparations: | 6 months |
| ii) Period which may be needed for collecting the data: | 6 months |
| iii) Period that may be required for analyzing the data: | 2 year |

6. Amount of Grant-in-aid asked for:

	Total	1 st Instalment	2 nd Instalment	3 rd Instalment	Remaining Amount (10%)	Withheld amount (10%)
Salary - Research Associate - 1. (23,000/-pm as per AYUSH norms)	8,28,000	2,20,800	2,20,800	2,20,800	82800	82800
Equipment Stability Chamber Make: EIE Instruments Pvt., Limited.	1,18,000	1,18,000	--	--	--	--
Books	--	--	--	--	--	--
Other Non-Recurring Expenditure Equipments	--	--	--	--	--	--
Recurring Expenditure, Chemicals Marker Compounds etc.,	1,00,000	1,00,000	--	--	--	--
TA/DA	40,000	10,000	10,000	10,000	5,000	5,000
Institutional Support (-)	1,00,000	30,000	35,000	35,000	--	--
Fee of PI and Col	90,000 45,000	30,000 15,000	30,000 15,000	30,000 15,000	--	--
Miscellaneous Expenses	1,00,000	30,000	30,000	20,000	10,000	10,000
Total	12,21,000	4,93,800	2,70,800	2,60,800	97,800	97,800

7. DECLARATION AND ATTESTATION

Certified that:

I/We have read the provisions, terms and conditions, mentioned in the Extra-mural Scheme along with its Annexure, Guidelines formulated by the Ministry of AYUSH and I/we shall abide by the relevant provisions contained under EMR Scheme and General Financial Rules of Govt. of India.

Name and Signature of the:

a) Principal Investigator: Dr. V. Bodaninathu. 6/6/19

b) Co-Investigator(s): Dr. N. Hanishankar, 6/6/2019.

c) Head of the Department: Dr. Y. PHALGUNA 6/6/19

Signature of the Head of the Institute: Dr. Sai Krushna Padhy 6/6/19

07/06/19

BRIEF SUMMARY OF THE PROJECT PROPOSAL

So far, there is no universal cancer preventive formulation in the market. At present, the modern treatments for cancer are incomplete, costly, complex, dangerous (severe side effects) and unpleasant for patients as it requires long period of treatment. Allopathy still battles relentlessly to end of trauma of cancer patients. So far, there is no magic bullet that can win the cancer completely. On the other hand, chances for getting the cancer are increasing day by day and they were unavoidable. Various causes of cancer are current life style, decreased physical exercise, lack of micro, macro nutrients and antioxidants, in daily food, environmental agents like ionizing radiation, pollution, addiction to alcohol, tobacco, increased mental stress, use of cell phones, betel quid chewing, neglecting own health, careless usage of strong medicines, unnecessary use of antibiotics for long time, frequent treatment by steroidal drugs, early menarche, late menopause, obesity, hormone use, diabetes, occupational carcinogens.¹⁻¹²

However, avoiding or minimizing the human beings to expose these carcinogenic agents is practically not possible. Prevention is better than cure. Hence, it seems, cancer chemoprevention remains as ideal strategy in anticancer arsenal. Hence the objectives of the work –

- To develop safe and potential Herbo Mineral Formulation (HMF) for prophylactic use of cancer.
- To prepare conventional oral tablets, by using Green tea and Sodium Selenite for prophylactic use of all types of cancers. To standardize the developed formulation according to regulatory guidelines. To perform the Quality control, Safety, and Efficacy evaluation of the Formulation. To quantify the chemopreventive activity (prominent effect) of the formulation in the laboratory animals against above cancers.
- To prove its anticancer activity (reverse of cancer) in human cancer cell line studies.

DETAILED RESEARCH PROTOCOL

Criteria for the Selection of Herbals for Formulation

Among the various herbals, *Camellia sinensis* (Green tea) was selected due to its following extraordinary properties.

- Shows affordable protection against most types of cancers like lung, liver, esophagus, fore stomach, duodenum, pancreas, colon, and breast.
- Economical, widely available and non-toxic.
- Nearly all the constituents of the green tea possess antioxidant activity.
- Proved as chemopreventive in animal as well as epidemiology studies.
- It is in final stage of human clinical trials by U.S. National Cancer Institute.
- It prevents treats as well as reverses the cancer.
- Protective against genotoxic damage induced by anticancer drugs like Cyclophosphamide and Methane sulphonate.
- Associated with many other major health benefits like lowering cholesterol, elevated blood pressure, elevated blood sugar and boosting of immune system.

Criteria for the Selection of Mineral for Formulation

Among the various minerals, Sodium Selenite was selected due to its following suitable properties.

- Selenium is present in our body as a part of various antioxidant enzymes. Recognized and listed by National Cancer Institute, United States.
- It prevents major cancers like Liver, Stomach, Oral, Colon, Lung, Prostate etc.
- Comparatively safe mineral. Have potential chemopreventive and anticancer effects.
- Proved in animal and epidemiology studies. Daily consumption of Selenium throughout the world is very less & this leads to cancer.

Economical and widely available. Essential for our body.

WORK PROTOCOL

Procurement of Materials

- Selection of Herbal and Mineral Compounds for formulation
- Preparation of Aqueous extract of Green Tea Leaves
- Standardization of Aqueous extract of Green Tea Leaves
- Quantification of Green Tea Catechin Contents by HPTLC
- Procurement of Mineral compound Sodium Selenite

Development of Formulation

- Pre formulation Studies (Flow Properties & Derived Properties)
- Drug Incompatibility Studies by FTIR
- Preparation of Tablets by Wet Granulation (6 Formulations)
and Direct Compression methods (6 Formulations)
- Packing of Tablets (Blister Packing)
- Evaluation of Formulations (Physico chemical Evaluation)
- Dissolution (8 basket dissolution apparatus, Paddle)

Standardization of Formulation

- Standardization of Green Tea content in tablets by HPTLC Finger Printing
(Comparing the peak areas with marker compounds)
- Standardization of Sodium Selenite in tablets by ICP-MS

Quality Assessment

- Shelf life Estimation as per ICH guide lines
- Microbial Evaluation of Tablets (Microbial Load Determination)

Efficacy Assessment

Toxicological Evaluation of Tablets

(Acute Oral Toxicity Studies as per OECD guidelines)

Efficacy Assessment

In-vivo animal Chemopreventive Studies

Selection of an animal model which mimics or duplicates the human experience in experimental animals was selected for this study.

- Prevention of Lung Cancer Induced by Tobacco Smoking in Mice
- Prevention of Liver Cancer induced by alcohol in Mice
- Prevention of Skin cancer Induced by UV rays in Mice
- Prevention of Colon Cancer Induced by Azoxymethane in Rats

Cancer Cell line Studies in human lung and skin cancer cells

Government of India
Ministry of Environment, Forest and Climate Change

Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA)
5th Floor, Vayu Block, Indira Paryavaran Bhawan, Jor Bagh Road, New Delhi

CERTIFICATE

This is to certify that the registration of Animal House Facility of Bharat Institute of Technology ~ Pharmacy, Ranga Reddy District, Telangana with CPCSEA has been renewed for Research for Education purpose on Small Animals bearing registration number 1015/PO/Re/S/06/CPCSEA.

The registration is valid for five years from 26/09/2018 to 25/09/2023.

(Jerome Minz)

Deputy Secretary (AW) & Member Secretary (CPCSEA)

JEROME MINZ

Member Secretary (CPCSEA)
Min. of Environment, Forest & Climate Change
Government of India
Jor Bagh Road, New Delhi

PROPOSAL FOR INDUSTRIAL PROJECT
BUDGET ESTIMATE= Rs/- 50000

TITLE: PRECLINICAL ANTIDIABETIC STUDIES OF POLYHERBAL
FORMULATION ON STREPTOZOTOCIN INDUCED DIABETIC RATS.

ABSTRACT

Necessity of work:

Plants are very useful to mankind. Many of them are used exclusively for medicinal purposes. According to the World Health Organization (WHO), "a medicinal plant is a plant which, in one or more of its organs, contains substances that can be used for therapeutic purposes, or which are precursors for chemo-pharmaceutical semi-synthesis." Such plants are in great demand by pharmaceutical companies for their active ingredients.

Diabetes mellitus is one of the most common disorders affecting almost 6% of the world population and the dynamics of the diabetes are changing rapidly in low- to middle-income countries. According to International Diabetes Federation's (IDF) estimates, 80% of the world diabetic population will be from low- and middle- income countries in 2030. Globally, diabetes is one of the six major causes of death and also causing various systemic complications. Diabetes mellitus is treated by hormone therapy (insulin) or by administering glucose- lowering agents such as alpha-glucosidase inhibitors, sulfonylureas, biguanides, and thiazolidinediones.

Development of an adverse event is one of the complications in the treatment of any systemic disorder; hence, many of the research institutes and pharmaceutical companies are involved in drug development to find the molecules with good therapeutic potential and less adverse events. In traditional systems of medicine, many plants have been documented to be useful for the treatment of various systemic disorders. Many of the traditional/indigenous systems of medicine are effective than the modern system of medicine, but they suffer from lack



of complete standardization which is one of the important challenges faced by the traditional system of medicine. The concept of polyherbal formulation is well documented in the ancient literature. Compared to the single herb, the polyherbal formulation has better and extended therapeutic potential. Hence, the present study was planned to formulate and standardize a polyherbal formulation using a plant having known antidiabetic activity and evaluate its therapeutic effects in rodents.

Aim and Objectives:

- ❖ The aim of the present study is to formulate a polyherbal formulation and evaluate its antidiabetic potential in animals.
- ❖ The quality of the finished product will be evaluated as per the World Health Organization's guidelines.
- ❖ Fingerprint analysis of the polyherbal formulation will be carried out to confirm the active compound present in the polyherbal formulation are same or not.
- ❖ The acute toxicity studies will be carried out for the determination of mortality rate and to fix the dose(s) of the formulation.
- ❖ The oral antidiabetic activity of the polyherbal formulation will be screened against streptozotocin induced diabetes mellitus in rats.

Plan of Work:

The plan of work for the project is described with following points:


- ❖ Collection of the plants, preparation of extracts and phytochemical analysis.
- ❖ Preparation of polyherbal formulation by wet granulation method.
- ❖ Preformulation studies and standardization of formulations.
- ❖ High-performance thin layer chromatography (HPTLC) fingerprint analysis.
- ❖ Development of quality control standards for the polyherbal capsule.
- ❖ Acute oral toxicity studies for dose fixation.
- ❖ Antidiabetic effect of herbal formulation in streptozotocin induced diabetic rats.



Chemical analysis and Histopathologic analysis study.
❖ Result analysis.

Importance of the work:

The major importance of the work will be formulation of a polyherbal drug, which will be standardized by using standard methods. The effectiveness of the active metabolites present in the extracts will be determined and quality control standards for polyherbal capsules will be development. The anti-diabetic activity studies of the polyherbal formulation will be carried out and data will be analyzed for the prescribed studies.



Proposed plan of work by

Dr. Mrinmay Das

HOD, Dept. of Pharmaceutical Chemistry, BIT.

PROPOSAL FOR INDUSTRIAL PROJECT
BUDGET ESTIMATE = Rs/- 50000

**TITLE: INTRANASAL *IN SITU* GEL NANOPARTICLES OF ANTICANCER DRUGS
FOR BRAIN TARGETING**

ABSTRACT

Necessity of work: Nasal drug delivery system provides an alternative route for the Drugs which cannot be absorbed orally. Nasal drug delivery is an efficient alternate route for systemic delivery of orally inefficient drugs. It also offers non-invasive delivery of potent peptide and perhaps protein drug molecules. The intranasal route is an accessible alternative to parenteral routes. The need for safe and effective nasal permeation and absorption enhancers is a major component for a promising future in the area of nasal drug delivery. It reduces systemic exposure and thus reduces the side effects.

AIM: The aim of the proposed research is to develop novel and stable lipid nano formulations for anticancer drugs i.e., a nanoemulsion at room temperature and turns to gel at nasal temperature for intranasal administration.

Objectives: The objectives are (1) to develop novel and stable nano particulate formulations of anticancer drugs and incorporating into an in situ gel, (2) optimization of formulation parameters using experimental designs, (3) to evaluate various physicochemical properties of these formulations, (4) to investigate the drug loading efficiency and gelation characteristics. (5) to study the stability of the developed formulations at room temperature (25°C), (6) to investigate the distribution of anticancer drugs in to the brain and cerebro spinal fluid from the formulation after intra nasal administration.

Plan of Work:

Preparation of various nanoparticulate formulations of drugs using polymers Incorporation of nanoparticle into in situ gels using lipid based polymers and emulsifiers. Eg. Triolein as lipid phase, phosphatidyl choline as surfactant 1, and a combination of poloxamer F68 and F127 as surfactant 2 were used based on literature analysis for the present study. Evaluation of intranasal insitu gels of nanoparticles: Various parameters such as preformation studies, gelation temperature, pH, drug content uniformity, particle size distribution, zeta potential, mucoadhesive strength, rheological properties, in vitro drug release studies, stability studies, lyophilization, and pharmacokinetic parameters evaluation.



Proposed plan of work by: Dr. Y. Phalguna

HOD, Dept. of Pharmaceutics, BIT.

BHARAT INSTITUTE OF TECHNOLOGY: MANGALPALLY

PROPOSAL FOR INDUSTRIAL PROJECT

BUDGET ESTIMATE = Rs. 50,000/-

TOPIC: DEVELOPMENT OF INSTRUMENT "TOBACCO SMOKE INDUCED LUNG CANCER CHAMBER"
AS A EFFECTIVE NATURAL ANIMAL MODEL

ABSTRACT



NECESSITY OF WORK: Inducing lung cancer in animals is essential step to develop anti cancer drugs. At present, all the models are using chemicals to induce the cancer in animal lungs. Developing the cancer in animals that mimics like in human (Cigarettes) is the idea of the present proposal.

AIM: This proposal is aimed at development of naturally inducing lung cancer animal model in the line of development of anticancer drugs.

OBJECTIVE: To design, develop and getting patents the instrument "TOBACCO SMOKE INDUCED LUNG CANCER CHAMBER".

OUT-COME:-

PROPOSED IDEAL DESIGN AND DRAWINGS IN GRAPHICS



A.V. Badari Nath

Proposed and Pictures Drawn by: Dr. A.V. Badari Nath, Professor, BIT.